Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ACR appropriateness criteria follow-up of Hodgkin lymphoma.
Ha CS, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith S, Terezakis SA, Winkfield KM, Younes A, Constine LS. Ha CS, et al. Among authors: smith s. J Am Coll Radiol. 2014 Nov;11(11):1026-1033.e3. doi: 10.1016/j.jacr.2014.07.038. Epub 2014 Sep 30. J Am Coll Radiol. 2014. PMID: 25278496
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Advani RH, et al. Among authors: smith sm. J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8. J Clin Oncol. 2013. PMID: 23045577 Free PMC article. Clinical Trial.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA. Evens AM, et al. Among authors: smith sm. Am J Hematol. 2015 Sep;90(9):778-83. doi: 10.1002/ajh.24082. Am J Hematol. 2015. PMID: 26044261 Free article.
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Barr PM, et al. Among authors: smith sm. J Clin Oncol. 2015 Jul 20;33(21):2399-404. doi: 10.1200/JCO.2014.60.6327. Epub 2015 Jun 15. J Clin Oncol. 2015. PMID: 26077240 Free PMC article. Clinical Trial.
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.
Dabaja BS, Advani R, Hodgson DC, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. Dabaja BS, et al. Among authors: smith sm. Am J Clin Oncol. 2015 Dec;38(6):610-20. doi: 10.1097/COC.0000000000000215. Am J Clin Oncol. 2015. PMID: 26583344 Review.
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM. Advani RH, et al. Among authors: smith sm. Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2. Br J Haematol. 2016. PMID: 26627450 Free PMC article. Clinical Trial.
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS; Expert Panel on Radiation OncologyLymphoma. Roberts KB, et al. Among authors: smith sm. Am J Clin Oncol. 2016 Aug;39(4):384-95. doi: 10.1097/COC.0000000000000294. Am J Clin Oncol. 2016. PMID: 27299425 Review.
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS; Expert Panel on Radiation Oncology–Lymphoma. Dhakal S, et al. Among authors: smith sm. Am J Clin Oncol. 2016 Dec;39(6):535-544. doi: 10.1097/COC.0000000000000331. Am J Clin Oncol. 2016. PMID: 27643717 Free PMC article. Review.
21,653 results
You have reached the last available page of results. Please see the User Guide for more information.